[Carcinoma of the adrenal cortex].
We present nine cases of primary adrenocortical carcinoma, collected in our department of medicine and endocrinology over 25 years. In our patients, the most dependable tumor marker was urinary excretion of tetra-hydro-ll-deoxycortisol (THS), and elevated values were found in all cases where it was determined. In addition to surgical treatment, medication with o,p'-DDD was found to be of value for some of the patients. Median tumor weight was 487 g (118-2,085 g). Prognosis is difficult to predict. Median survival time after diagnosis was 34 months, but varied from three to 266 months.
Hamborg
B
B
Medisinsk avdeling B, Aker sykehus, Oslo.
Frey
H
H
Bøhmer
T
T
Norman
N
N
D015068:17-Ketosteroids / Q000652:urine; D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000652:urine; D003350:Cortodoxone / Q000031:analogs & derivatives / Q000652:urine; D003480:Cushing Syndrome / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011379:Prognosis
D015068:17-Ketosteroids; D014408:Biomarkers, Tumor; C009412:tetrahydro-11-deoxycortisol; D008939:Mitotane; D003350:Cortodoxone; D006854:Hydrocortisone
Karsinom i binyrebarken.